(Q42691726)

4 November 2017

title

Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration (English)

1 reference

4 November 2017

1 reference

1 reference

1

1 reference

4 November 2017

Neumann F

2

1 reference

4 November 2017

Bremer F

3

1 reference

4 November 2017

Brune K

4

1 reference

4 November 2017

Lötsch J

5

1 reference

4 November 2017

Geisslinger G

6

1 reference

4 November 2017

language of work or name

English

0 references

publication date

1 January 1999

1 reference

Clinical Pharmacology & Therapeutics

4 November 2017

published in

1 reference

4 November 2017

volume

65

1 reference

4 November 2017

issue

1

1 reference

4 November 2017

page(s)

50-57

1 reference

The carbapenems: new broad spectrum beta-lactam antibiotics

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

Pharmacokinetics of meropenem in animals, healthy volunteers, and patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

Pharmacokinetics of meropenem in subjects with renal insufficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

Pharmacokinetics of meropenem in subjects with various degrees of renal impairment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

Multiple-dose study of imipenem/cilastatin in patients with end-stage renal disease undergoing long-term hemodialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

Imipenem/cilastatin: pharmacokinetic profile in renal insufficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

Removal of imipenem and cilastatin by hemodialysis in patients with end-stage renal failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

Comparison of pump-driven and spontaneous continuous haemofiltration in postoperative acute renal failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

Continuous veno-venous hemofiltration in critically ill patients with multiple organ failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

Continuous arteriovenous hemofiltration in acute renal failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

Imipenem/cilastin dosage during acute renal failure and hemofiltration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

High-performance liquid chromatographic assay for meropenem in serum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

Determination of pharmacokinetic constants after multiple infusions of drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

The disposition and metabolism of meropenem in laboratory animals and man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

The pharmacokinetics of meropenem in volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

Disposition of radiolabeled imipenem and cilastatin in normal human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

Integration of Selected Pharmacologic and Microbiologic Properties of Three New -Lactam Antibiotics: A Hypothesis for Rational Comparison

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

Correlation between pharmacokinetics, pharmacodynamics and efficacy of antibacterial agents in animal models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

Postantibiotic effect of meropenem on members of the family Enterobacteriaceae determined by five methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

Pharmacodynamic effects of meropenem on gram-negative bacteria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

Comparison of methodologies used in assessing the postantibiotic effect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

The postantibiotic effect of meropenem and imipenem on selected bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

In vivo and in vitro study of several pharmacodynamic effects of meropenem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

Pharmacokinetics of meropenem in patients with intra-abdominal infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5 min and intravenous infusion over 30 min

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

The postantibiotic effect of imipenem: relationship with drug concentration, duration of exposure, and MIC

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970121-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0009-9236(99)70121-9

1 reference

4 November 2017

1 reference